Kura Oncology Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kura Oncology Inc 's ROA in the second quarter of 2026?
Kura Oncology Inc recorded a cumulative net loss of $-297 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -45.17%.

However, within the Healthcare sector 530 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3839, from total ROA ranking in the first quarter of 2026 at 4448.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-13.87 %	-12.24 %	-2.6 %	35.71 %	32.48 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-297	-295	-279	-217	-197
Return On Assets (TTM)	-45.17 %	-43.28 %	-39.62 %	-30.62 %	-29.62 %
KURA's Total Ranking	# 3839	# 4448	# 3778	# 3777	# 3831
Total Assets (TTM) in million	588	653	738	649	682
Seq. Total Assets Change	-9.92 %	-11.62 %	13.7 %	-4.84 %	-8.22 %
Seq. Net Income Change	-	-	-	-	-

KURA's 5 Years Annual ROA >> Back to KURA Management Effectiveness >> Compare KURA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 221
Sector	# 531
Overall	# 3833

Return On Assets Statistics
High	Average	Low
-20.53 %	-71.86 %	-345.9 %
(Sep 30 2021)		(Dec 31 2014)

Financial Statements
Kura Oncology Inc 's Assets	$ 588 million	KURA's Balance sheet
Kura Oncology Inc 's Income	$ -68 million	Quarterly KURA's Income Statement
KURA's Income by Division		See KURA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-2.87 %	69.32 %	-1.62 %	-14.56 %	-17.48 %
Total Assets in million	738	760	449	456	534
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-279	-174	-153	-136	-130
Annual Return On Assets	-37.74 %	-22.89 %	-34 %	-29.77 %	-24.43 %

KURA's 5 Years Annual ROA >> Back to KURA Management Effectiveness >> Compare KURA ROA to its Competitors

More Return On Assets Ratios
KURA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KURA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KURA's Competitors
Subscribers only: Roa for Kura Oncology Inc 's Suppliers
Subscribers only: Return On Assets for KURA's Customers

You may also want to know
KURA's Roi	KURA's Inventory Turnover Ratio	KURA's Growth Rates	KURA's Dividend Comparisons
	KURA's Profitability Ratios	KURA's Asset Turnover Ratio	KURA's Dividend Growth
KURA's Roe	KURA's Valuation Ratios	KURA's Financial Strength Ratios	KURA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:19:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.